During tumor progression, CAPZA1, GRB2, NF2EL3, PLEKHO1, SIGLEC1, and UBE2Z were expressed at higher levels in late-stage KIRC, whereas EMX2, FUCA1, IMPA2, and RORC were expressed at higher levels in early-stage KIRC (Figure 6(b)). The gene discussed is IMPA2; the disease is neoplasm.